Predicting 30-day reoperation following primary total knee arthroplasty: machine learning model outperforms the ACS risk calculator.

Journal: Medical & biological engineering & computing
PMID:

Abstract

The ACS risk calculator (ARC) has proven less effective in predicting patient-specific risk of early reoperation after primary total knee arthroplasty (TKA), compromising care quality and cost efficiency. This study compared the performance of a machine learning (ML) model and ARC in predicting 30-day reoperation after primary TKA using a national-scale dataset. Data of 366,151 TKAs were acquired from the ACS-NSQIP database. A random forest model was derived using ARC build-in parameters from the training dataset via techniques of hyperparameter optimization and cross-validation. The predictive performance of random forest and ARC was evaluated by metrics of discrimination, calibration, and clinical utility using the testing dataset. The ML model demonstrated good discrimination and calibration (AUC: 0.72, slope: 1.18, intercept: - 0.14, Brier score: 0.012), outperforming ARC in all metrics (AUC: 0.51, slope: - 0.01, intercept: 0.01, Brier score: 0.135) including clinical utility measured by decision curve analyses. Age (> 67 years) and BMI (> 34 kg/m) were the important predictors of reoperation. This study suggests the superiority of ML models in identifying individualized 30-day reoperation risk following TKA. ML models may be an adjunct prediction tool in enhancing patient-specific risk stratification and postoperative care management.

Authors

  • Tony Lin-Wei Chen
    Bioengineering Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Anirudh Buddhiraju
    Bioengineering Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Blake M Bacevich
    Bioengineering Laboratory, Department of Orthopaedic Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Henry Hojoon Seo
    Bioengineering Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Michelle Riyo Shimizu
    Bioengineering Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Young-Min Kwon